4th Feb 2022 14:37
Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Calls extraordinary general meeting for February 28 to approve a 50-into-1 share consolidation. Sareum says its current large number of shares, at 3.40 billion, and low share price create a negative perception among investors. Reducing the number of shares by a factor of 50 will increase the share price and make the stock "more attractive to a broader range of investors", it says.
Current stock price: 3.92 pence
12-month change: doubled from 1.90p
By Tom Waite; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Sareum